Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Maël Heiblig; Marcela A. Ferrada; Matthew T. Koster; Thomas Barba; Mathieu Gerfaud-Valentin; Arsène Mékinian; Henrique Coelho; Gaelle Fossard; Fiorenza Barraco; Lionel Galicier; Boris Bienvenu; Pierre Hirsch; Guillaume Vial; Anne Blandine Boutin; Joris Galland; Guillaume Le Guenno; Adrien Bigot; Kenneth J. Warrington; Tanaz A. Kermani; Peter C. Grayson; Bhavisha A. Patel; David B. Beck; Yvan Jamilloux; Pierre Fenaux; Pierre Sujobert

doi:10.1182/blood.2022016642

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Maël Heiblig, Marcela A. Ferrada, Matthew T. Koster, Thomas Barba, Mathieu Gerfaud-Valentin, Arsène Mékinian, Henrique Coelho, Gaelle Fossard, Fiorenza Barraco, Lionel Galicier, Boris Bienvenu, Pierre Hirsch, Guillaume Vial, Anne Blandine Boutin, Joris Galland, Guillaume Le Guenno, Adrien Bigot, Kenneth J. Warrington, Tanaz A. Kermani, Peter C. GraysonBhavisha A. Patel, David B. Beck, Yvan Jamilloux, Pierre Fenaux, Pierre Sujobert

Rheumatology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	927-931
Number of pages	5
Journal	Blood
Volume	140
Issue number	8
DOIs	https://doi.org/10.1182/blood.2022016642
State	Published - Aug 25 2022

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2022016642

Cite this

Heiblig, M., Ferrada, M. A., Koster, M. T., Barba, T., Gerfaud-Valentin, M., Mékinian, A., Coelho, H., Fossard, G., Barraco, F., Galicier, L., Bienvenu, B., Hirsch, P., Vial, G., Boutin, A. B., Galland, J., Le Guenno, G., Bigot, A., Warrington, K. J., Kermani, T. A., ... Sujobert, P. (2022). Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood, 140(8), 927-931. https://doi.org/10.1182/blood.2022016642

Heiblig, M, Ferrada, MA, Koster, MT, Barba, T, Gerfaud-Valentin, M, Mékinian, A, Coelho, H, Fossard, G, Barraco, F, Galicier, L, Bienvenu, B, Hirsch, P, Vial, G, Boutin, AB, Galland, J, Le Guenno, G, Bigot, A, Warrington, KJ, Kermani, TA, Grayson, PC, Patel, BA, Beck, DB, Jamilloux, Y, Fenaux, P & Sujobert, P 2022, 'Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study', Blood, vol. 140, no. 8, pp. 927-931. https://doi.org/10.1182/blood.2022016642

@article{bd0c564783dd4fb089f5c49b86d617e0,

title = "Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study",

author = "Ma{\"e}l Heiblig and Ferrada, {Marcela A.} and Koster, {Matthew T.} and Thomas Barba and Mathieu Gerfaud-Valentin and Ars{\`e}ne M{\'e}kinian and Henrique Coelho and Gaelle Fossard and Fiorenza Barraco and Lionel Galicier and Boris Bienvenu and Pierre Hirsch and Guillaume Vial and Boutin, {Anne Blandine} and Joris Galland and {Le Guenno}, Guillaume and Adrien Bigot and Warrington, {Kenneth J.} and Kermani, {Tanaz A.} and Grayson, {Peter C.} and Patel, {Bhavisha A.} and Beck, {David B.} and Yvan Jamilloux and Pierre Fenaux and Pierre Sujobert",

note = "Funding Information: This study was not funded by a specific grant. ",

year = "2022",

month = aug,

day = "25",

doi = "10.1182/blood.2022016642",

language = "English (US)",

volume = "140",

pages = "927--931",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "8",

}

TY - JOUR

T1 - Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome

T2 - a retrospective multicenter study

AU - Heiblig, Maël

AU - Ferrada, Marcela A.

AU - Koster, Matthew T.

AU - Barba, Thomas

AU - Gerfaud-Valentin, Mathieu

AU - Mékinian, Arsène

AU - Coelho, Henrique

AU - Fossard, Gaelle

AU - Barraco, Fiorenza

AU - Galicier, Lionel

AU - Bienvenu, Boris

AU - Hirsch, Pierre

AU - Vial, Guillaume

AU - Boutin, Anne Blandine

AU - Galland, Joris

AU - Le Guenno, Guillaume

AU - Bigot, Adrien

AU - Warrington, Kenneth J.

AU - Kermani, Tanaz A.

AU - Grayson, Peter C.

AU - Patel, Bhavisha A.

AU - Beck, David B.

AU - Jamilloux, Yvan

AU - Fenaux, Pierre

AU - Sujobert, Pierre

N1 - Funding Information: This study was not funded by a specific grant.

PY - 2022/8/25

Y1 - 2022/8/25

UR - http://www.scopus.com/inward/record.url?scp=85133598072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133598072&partnerID=8YFLogxK

U2 - 10.1182/blood.2022016642

DO - 10.1182/blood.2022016642

M3 - Letter

C2 - 35609174

AN - SCOPUS:85133598072

SN - 0006-4971

VL - 140

SP - 927

EP - 931

JO - Blood

JF - Blood

IS - 8

ER -

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this